Sci Transl Med August 2023 PMID 37556556

Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.

Jinshi Zhao, C Skyler Cochrane, Javaria Najeeb, David Gooden, Carly Sciandra, Ping Fan, Nadine Lemaitre, Kate Newns, Robert A Nicholas, Ziqiang Guan, Joshua T Thaden, Vance G Fowler, Ivan Spasojevic, Florent Sebbane, Eric J Toone

Download social card

Mentions

Peak: 9 in Aug 2023

across 4 sources since Aug 2023

Extended reach

74,215

potential audience

Total likes

Video views

Mentions per month

Aug 2023 – Sep 2024

Where it's discussed

News21 articles
X / Twitter19 posts
Blogs3 articles
YouTube2 videos

AI synopsis

What people are saying

The discussions highlight enthusiasm for the promising new antibiotic targeting LpxC, with phrases like 'great paper,' 'new antibiotic,' and 'a glimmer of hope,' emphasizing excitement about its potential. The tone is optimistic and focused on the significance of safety and efficacy findings, reflecting strong interest and engagement while recognizing the potential shift in treating resistant bacteria.

AgreementModerate agreement

Most discussions express optimism about the research findings and the potential of the new antibiotic, indicating general agreement on its promise.

InterestHigh interest

The discussions show high engagement with the topic, focusing on the significance of targeting LpxC and the promising results, reflecting solid interest.

EngagementModerate engagement

Posts that mention specific details like safety, efficacy, and potential for clinical use demonstrate active engagement with the subject.

ImpactModerate impact

There is a shared belief that this research could have a meaningful impact on treating multidrug-resistant infections, though some caution remains.

Abstract in brief

LpxC is a crucial enzyme for producing lipid A, a key component of the outer membrane in Gram-negative bacteria, but creating effective LpxC-targeting antibiotics has faced challenges due to toxicity and limited efficacy of current inhibitors.
LPC-233 is a promising new antibiotic that binds tightly to LpxC, shows strong antibacterial activity against a variety of Gram-negative bacteria, and is effective in treating infections in animal models.
This compound has a favorable safety profile, exhibiting no significant cardiovascular side effects at high doses, suggesting it could lead to new oral antibiotics for clinical use.

Read the full abstract

All mentions

LpxC Inhibitor LPC-233: A Promising Antibiotic Against Gram-Negative Bacteria

Dr. Pei Zhou discusses LPC-233, an LpxC inhibitor with bactericidal activity against Gram-negative bacteria. This compound shows strong efficacy, safety in animal models, and potential as a new oral antibiotic targeting…

Let's Talk Micro · Aug 1, 2024 36 views

LpxC Inhibitor LPC-233: New Approach to Combating Gram-negative Bacteria

In this episode, Dr. Pei Zhou discusses LPC-233, a promising LpxC inhibitor with bactericidal activity against Gram-negative rods. The compound shows strong antibacterial effects and a favorable safety profile, paving…

Let's Talk Micro · Sep 7, 2024 24 views

Logan Kavanaugh (she/her)

@IN_LOGan_PHASE · X